Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, Simon R, Wilczak W, Izbicki J, Sauter G, Minner S, Schlomm T, Steurer S. Grupp K, et al. Among authors: sirma h. Exp Mol Pathol. 2013 Oct;95(2):227-34. doi: 10.1016/j.yexmp.2013.08.002. Epub 2013 Aug 12. Exp Mol Pathol. 2013. PMID: 23948277
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, Izbicki JR, Pantel K, Dikomey E, Korbel JO, Plass C, Sauter G, Schlomm T, Minner S. Kluth M, et al. Among authors: sirma h. Mod Pathol. 2013 Jul;26(7):975-83. doi: 10.1038/modpathol.2012.236. Epub 2013 Feb 1. Mod Pathol. 2013. PMID: 23370768 Free article.
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, Sirma H, Simon R. Burkhardt L, et al. Among authors: sirma h. Cancer Res. 2013 May 1;73(9):2795-805. doi: 10.1158/0008-5472.CAN-12-1342. Epub 2013 Mar 14. Cancer Res. 2013. PMID: 23492366
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H. Krohn A, et al. Among authors: sirma h. J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223. J Pathol. 2013. PMID: 23794398
SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis MC, Izbicki JR, Sauter G, Schlomm T, Wilczak W. Grupp K, et al. Among authors: sirma h. Prostate. 2013 Nov;73(15):1690-8. doi: 10.1002/pros.22707. Epub 2013 Jul 10. Prostate. 2013. PMID: 23843146
High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC. Grupp K, et al. Among authors: sirma h. Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26. Mod Pathol. 2014. PMID: 23887301 Free article.
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, Hube-Magg C, Salomon G, Graefen M, Heinzer H, Minner S, Izbicki JR, Sauter G, Schlomm T, Tsourlakis MC. Grupp K, et al. Among authors: sirma h. Mol Oncol. 2013 Dec;7(6):1001-11. doi: 10.1016/j.molonc.2013.07.009. Epub 2013 Jul 19. Mol Oncol. 2013. PMID: 23941784 Free PMC article.
βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A. Tsourlakis MC, et al. Among authors: sirma h. Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28. Am J Pathol. 2014. PMID: 24378408
69 results